AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06261125 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.
Study NCT06261125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.
Study NCT06261125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
Study NCT06525844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative endodontic therapy using I-PRF
Description: Blood will be taken from medial cubital vein
Study NCT06525844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood clot
Description: Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
Study NCT04845945 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV15
Description: Blood draw after the vaccination
Study NCT04874402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prepectoral approach
Description: Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device
Study NCT04874402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Subpectoral approach
Description: The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
Study NCT05035914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
Study NCT06457074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone Oral Tablet
Description: Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Study NCT06457074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone Oral Tablet
Description: Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Study NCT04421482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard room temperature (RTS) feeding of milk/formula
Description: Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions: standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
Study NCT04421482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold temperature (CS, at 4-9°C) of milk/formula
Description: Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions, standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
Study NCT06372587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetically encoded engineered proteins
Description: using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
Study NCT06372587 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: genetically encoded engineered proteins
Description: using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
Study NCT06257017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
Study NCT06257017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: 1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
Study NCT06257017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
Study NCT06257017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
Study NCT05214183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Description: Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
Study NCT04409808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRIS
Description: prototype IRIS vitrectomy device.
Study NCT06178029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation and acupuncture treatment.
Study NCT06527352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: glottis mask airway
Description: the glottis mask airway is used for maintaining ventilation during general anesthesia
Study NCT06527352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tulip shaped
Description: the tulip shaped mask airway is with a tulip shaped tip
Study NCT06527352 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: classical shaped
Description: the classical shaped mask airway is with a water-drop shaped tip
Study NCT04750967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months
Study NCT04750967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline 25 mg daily
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule (Part 1)
Description: At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively.
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug A Utidelone Capsule (Part 2: Group A-B)
Description: Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle.
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug A Utidelone Capsule (Part 2: Group B-A)
Description: Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle.
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug B Utidelone Injection (Part 2: Group A-B)
Description: Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle.
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug B Utidelone Injection (Part 2: Group B-A)
Description: Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle.
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
Study NCT06178029 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: 20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation
Study NCT05846490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure + anti-hypertensive treatment intensification (if necessary)
Study NCT05846490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Anti-hypertensive treatment intensification (if necessary)
Study NCT05700084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule (Part 3)
Description: Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.
Study NCT06423755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming programme
Description: A session plan will be followed, which included aims, objectives, learning outcomes and suggested core aquatic skills and swimming activities under each section. The session will consist of a session brief, a warmup, core aquatic skills, swimming strokes (front crawl, backstroke, breaststroke, and hybrid strokes), a cool down and a session debrief; following the guidance developed in study three.
Study NCT06423755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy care
Description: Treatment delivered by the physiotherapist could include exercise, advice, education, and manual therapy; they will be offered up to 6 sessions.
Study NCT05200130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Group
Description: The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
Study NCT05200130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Group
Description: Manual Therapy includes deep friction massage and myofascial relaxation techniques to shoulder and neck complex, active and resistant shoulder complex movements, shoulder complex mobilization, mobilization cervical joints.~The home exercise program includes an educational training program and posture correction exercises. The program includes stretching and strengthening exercises of the neck and shoulder complex.
Study NCT05200130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: The telerehabilitation program applied to the same home exercise group. In addition, to the home exercises, these patients will apply active mobilization called self-mobilization. Self-myofascial release, active glenohumeral joint mobilization, thoracic mobilization, and active cervical mobilization.
Study NCT06397599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: denture adhesive
Description: use of adhesive for completely edentulous
Study NCT05009108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Purdue Pegboard Test
Description: At first, each person will be asked to fill in the informed agreement and answer short questionnaire. Than he/she will be tested by the Purdue Pegboard Test according to the Czech version of extended manuals for those tests in only one session. Audio recording of verbal instructions will be used and whole testing process will be video recorded which is necessary for establishing the internal variability and variability of results of the Purdue Pegboard Test.~The results will be used only for establishing of the variability and inter-rater reliability of the Purdue Pegboard Test, not for patients' other interventions.
Study NCT06181110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction
Description: This intervention is a non-pharmacological approach that targets various factors contributing to sleep and circadian problems. It incorporates evidence-based elements such as CBT for insomnia, IPSRT, chronotherapy, and motivation enhancement. The treatment consists of 8 sessions with 4 cross-cutting modules: case formulation, sleep and circadian education, motivational interviewing, and goal setting. Participants also receive 4 core modules addressing sleep-wake regularity, daytime functioning, correcting beliefs, and maintaining behavioral change. Additionally, 6 optional modules cater to specific sleep-wake patterns, addressing sleep efficiency, excessive time in bed, delayed/advanced sleep phase, sleep-related worry, complex sleep environments, and nightmares. Modules are delivered based on individual needs. Sessions include agenda setting, homework review, treatment content delivery, goal assignment, and session summarization.
Study NCT05152732 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VGB-R04
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Study NCT04911309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional exercise training
Description: 12 weeks functional exercise training twice per week, each session lasting 60 min
Study NCT04911309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy / treatment
Description: 12 weeks standard therapy / treatment
Study NCT05775588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery with endobronchial valve implantation
Description: the patient would undergo Lung volume reduction surgery with endobronchial valve implantation
Study NCT05605210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Neuromuscular electrical stimulation will be applied at two sites to induce fatigue with stimulation frequency specified at the Arm/Group Descriptions. The electrical stimulation parameters to generate the fatigue protocol will be: biphasic pulsed current, pulse duration of 2 ms, and on:off times of 5:10s. The fatigue protocol will be applied with a current intensity sufficient to generate an evoked torque at a level of 20% of the MVIC, which will be maintained throughout the protocol. NMES will be maintained until reaching an intervention time of 20 minutes, generating 80 evoked contractions.
Study NCT05642156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isolated Ultrafiltration (iso-UF)
Description: isolated Ultrafiltration
Study NCT05157321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS device will deliver repetitive trains of magnetic pulses using Magstim Rapid 2 with angulated figure of eight shaped coil. The device comprised two-channel Neuro-EMG-MS digital system for determining the motor threshold of the patients that will be used for establishing the threshold intensity for stimulation. The figure of eight-shaped coil generated a magnetic field of up to 4 Tesla that penetrates the cranium, enters into the soft tissue of the brain and henceforth stimulates the motor neurons.
Study NCT05157321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Sham Repetitive Transcranial Magnetic Stimulation
Study NCT05842512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Treatment for NASH
Study NCT05842512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for NASH
Study NCT06580379 — intervention group
Intervention type: PROCEDURE
Intervention: Spine surgery
Description: Spine surgery, such as fusion requiring the need for precise intraoperative registration and navigation
Study NCT06497894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Description: CBT-I is conducted in an individual setting according to the manual used in McCurry (1). Factors at the level of behavior, cognitions, and physiology that perpetuate sleep onset and sleep maintenance disorders are addressed. In addition, psychoeducation on sleep and sleep hygiene, stimulus control, sleep restriction, relaxation, structured worry time, cognitive restructuring, and relapse prevention are part of the training. Each session will include homework.
Study NCT06497894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Description: Standard-dose continuously-combined bio-identical HRT containing transdermal estradiol 1.5 mg/d (= 2 strokes of Oestrogel® Dispenser) and oral micronized progesterone (= 1 capsule of Utrogestan® 200). This combination is the most popular HRT regimen, as it has a neutral effect on lipids, glucose, haemostasis. Participants will receive a conventional prescription for the 2 products that are covered by all health insurances in Switzerland.
Study NCT06497894 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Hygiene
Description: Sleep hygiene refers to healthy sleep habits, e.g. food and drink choices, a regular sleep schedule, evening routine. Although being widely used in daily practice, sleep hygiene shows no significant effect as monotherapy in patients with an established insomnia. The sleep hygiene condition in this study is matched to CBT-I in frequency and intensity of contact.
Study NCT04620967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart (Iasp) in insulin pump
Study NCT04620967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart
Description: Fast-acting insulin aspart (Fiasp) in insulin pump
Study NCT06072703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim Rapid2 System
Description: The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction.
Study NCT06072703 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magstim Rapid2 System
Description: The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction.